Dear Editor,

Based on studies showing in vitro antiviral activity of chloroquine (CQ) and hydroxychloroquine (HCQ) on SARS-CoV-2 \[[@bib1]\], Belgian COVID interim guidelines rapidly (March 13th, 2020) recommended treating hospitalized patients suffering from severe COVID-19 with HCQ, 400 mg bid the first day followed by 200 mg bid for 4 additional days (for GFR \> 30 ml/min).

Despite some encouraging preliminary clinical data \[[@bib2],[@bib3]\], major concerns have been raised about the use of HCQ to treat COVID-19 [@bib4], particularly regarding potential cardiac toxicity (i.e. QTc increase and risk of *torsade de pointe*). Because HCQ has been safely used for many years for various indications (e.a. connective tissue diseases) [@bib5], we decided to follow interim Belgian guidance for all eligible patients hospitalized in our COVID-19 wards. Moreover, we decided to add azithromycin (AZM), 500 mg Id for 3 days, for selected patients, based on our knowledge of its antibiotic, immunomodulatory and possible antiviral actions \[[@bib3]\].

Between March 8 and April 15, 2020, a total of 114 patients with confirmed COVID-19 pneumonia were hospitalized in our dedicated units. Patient characteristics are summarized in [Table 1](#tbl1){ref-type="table"} . The mean age was 63 years and men represented 55.3%. A vast majority (n = 104) presented with severe disease and half (n = 59) had cardiovascular disease history. Other comorbidities are listed in [Table 1](#tbl1){ref-type="table"}. HCQ was administered to 107 patients after QTc evaluation by electrocardiogram (ECG). HCQ was avoided in patients under palliative care (n = 4), if QTc was over 500 msec (n = 1), and if patients had received prior treatment with CQ (n = 2). Mean initial QTc was 429 msec (Bazett formula used for correction). Biochemistry was followed on a regular basis, and ionic disturbances (hypokalemia, hypomagnesemia) were treated by supplementation if present. Repeat ECG was not systematically performed during HCQ treatment, except in case of drug-drug interaction which could potentially increase QTc (see footnote of [Table 1](#tbl1){ref-type="table"}). The main drug-drug interaction was driven by addition of AZM (n = 28). In this group, QTc was controlled at day 2 of combination therapy (n = 24). We observed a significant increase in mean QTc, from 418 to 433 msec (p \< 0,01 with paired *t*-test), but none of the patients showed a QTc over 500 msec.Table 1Characteristics of patients.Table 1No. Patients114Age, mean \[range\], years63 \[19--95\]Sex\
Male (%)\
Female (%)63 (55.3)\
51 (44.7)Patients with comorbidities (%)\
None\
Cardiovascular disease\
Hypertension\
COPD\
Diabetes\
Immunosuppression29 (25,4%)\
59 (51,8%)\
56 (49,1%)\
17 (14,9%)\
25 (21,9%)\
17 (14,9%)O^2^ sat. on admission. while breathing ambient air, mean \[range\], %90,1 \[55--99\]Clinical presentation[a](#tbl1fna){ref-type="table-fn"} (%)\
Mild disease\
Moderate disease\
Severe disease0 (0%)\
10 (8,8%)\
104 (91,2%)HCQ (%)107 (93.8)ECG pretreatment (% of HCQ)100 (93.4)QTc initial, mean \[range\] msec429 \[342--493\]Drug-drug interaction (% of HCQ)\
Azithromycin\
Other[b](#tbl1fnb){ref-type="table-fn"}34 (31.8)\
28 (26.2)\
6 (5.6)ECG CTRL at day 2 (% of patient w. drug-drug interaction)\
Azithromycin\
Other27 (79.4)\
24 (70.5)\
3 (8.8)[^1][^2]

Furthermore, in our entire cohort there were no sudden deaths nor syncope requiring resuscitation or ICU admission. All ICU admissions (n = 13) were linked to respiratory failure resulting from COVID-19 pneumonia. One patient on HCQ presented AV nodal reentry tachycardia in parallel with respiratory failure, and was successfully treated with adenosine. All deaths in our cohort (n = 12) were attributed to COVID-19 infection.

In conclusion, based on our clinical experience, no safety issues were encountered with the use of HCQ for the treatment of COVID-19. In coherence with recent data published here [@bib6], its association with AZM also seems to be safe, despite a significant increase of QTc that should be carefully monitored. The efficacy of HCQ and its combination with azithromycin on COVID-19 infection needs, of course, to be strengthened with further evidence from large randomized clinical trials. However, at this point of the COVID-19 pandemic, we find it relevant to share our clinical experience with this well-known, readily available compound (HCQ) which has limited contraindications and may help in the fight against this outbreak.
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[^1]: "Mild disease" was define as symptoms of upper respiratory infection (fever, fatigue, myalgia, cough, sore throat, runny nose, sneezing) or digestive symptoms (nausea, vomiting, abdominal pain, diarrhea); "moderate" as clinical (fever and cough) and radiological pneumonia (infiltrates) without hypoxemia; "severe" as clinical and radiological pneumonia with hypoxemia (O^2^ saturation \< 93%).

[^2]: Other consisted in escitalopram, citalopram, fluconazole, valproate, mirtazapine and olanzapine.
